Stockscreener 앱 받기
32.03
3.58%
-1.19
전일 마감가:
$33.22
열려 있는:
$33.36
하루 거래량:
1.07M
Relative Volume:
0.50
시가총액:
$3.15B
수익:
$669.43M
순이익/손실:
$-609.36M
주가수익비율:
-5.2456
EPS:
-6.1061
순현금흐름:
$-507.20M
1주 성능:
-10.71%
1개월 성능:
+31.54%
6개월 성능:
+33.07%
1년 성능:
+9.58%
1일 변동 폭
$31.91
$33.58
1주일 범위
$31.81
$35.79
52주 변동 폭
$18.29
$39.89
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
32.03 | 3.27B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
476.31 | 121.89B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.12 | 69.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
859.43 | 54.49B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.97 | 39.11B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.26 | 38.46B | 4.29B | 577.22M | 641.34M | 4.2086 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating - Moomoo
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm
(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com South Africa
Ultragenyx releases 2025 impact report on rare disease work - Investing.com
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times
Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative
Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire
Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa
Form 4 Ultragenyx For: 6 July By Investing.com - Investing.com South Africa
Ultragenyx CFO Howard Horn sells $155,644 in company shares - Investing.com
Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit - 富途牛牛
RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan
RARE DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultrage - The National Law Review
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, G - The National Law Review
Ultragenyx 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds - The National Law Review
Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story? - simplywall.st
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark - marketscreener.com
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell Midcap Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Dynamic Index - marketscreener.com
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Price to earnings forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:RARE) - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (BX:UP0) - TradingView
RARE Forecast — Price Target — Prediction for 2027 - TradingView
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity - Seeking Alpha
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. Ltd - MarketBeat
Ultragenyx grants 44,409 restricted stock units to 15 new non-executive officers as an inducement. - Pluang
Ultragenyx awards 44,409 RSUs to 15 new hires - Stock Titan
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
1.38%
자본화:
|
볼륨(24시간):